Barry Greenberg Email & Phone Number

Toronto has formidable research strength in the field of dementia and in diseases that frequently contribute to and/or underlie dementia (e.g. Parkinson’s disease, Dementia with Lewy Bodies, Frontal Temporal Dementia-ALS, psychiatric disorders, metabolic disease, cardiovascular disease). With globally renowned basic research such as programs in genetics and epigenetics of Alzheimer’s Disease, cognitive neuroscience, geriatrics, stroke, neurology, radiology, imaging and neurosurgery, Toronto has distinguished itself as a powerhouse in dementia-related discovery and translational research. Various institutions in the region, including Baycrest, the Centre for Addiction and Mental Health, Sunnybrook Health Sciences Centre, University Health Network, and St. Michael’s Hospital, have developed robust clinical/population research infrastructure, including state-of-the-art imaging, genetics and IT platforms, which are being harnessed to understand the complex set of disorders that result in clinical dementia. These leading institutions have access to large cohorts of patients in prodromal, early and established phases of neurodegenerative disease, and are developing or have already established cohorts of patients with conditions and co-morbidities that often interact with or cause dementia. We are in the process of fully harnessed the population research resource afforded by the Toronto region as a tool for discovery and translation of insights into improved diagnostics, preventive interventions and more effective treatments and algorithms of care, by co-ordinating relevant research expertise, integrating clinical and technology platforms and harnessing the clinical and basic research capacities across these key institutions. See www.tdra.ca

-- Developing comprehensive drug discovery platform across research hospitals affiliated with University Health Network (Toronto General, Princess Margaret, Toronto Western) ranging from preclinical target identification through proof of concept in early phase clinical trials, initially within the area of neurodegenerative disease, extending into other therapeutic areas including metabolic disease, arthritis, cardiology, transplantation and infectious disease with emphasis on co-morbidities-- Establishing alliances with other clinical and academic centers in Toronto to expand the scope of this platform-- Establishing alliances with biopharmaceutical industry to develop collaborations supporting partnered discovery projects and proof-of-principle clinical trials based on discovery efforts, technology platforms (i.e. extensive imaging capabilities), and use of biological samples from large well-characterized patient cohorts for biomarker analysis and validation

Toronto, Canada Area

As the Krembil Discovery Tower goes up adjacent to the Toronto Western Hospital to expand the University Health Network's Neuroscience program, helping to hold the rudder as a formal search opens for a permanent Director. Working with space planning, appointment strategies, seminar series, outreach, supporting fundraising, and administrative duties.

Preclinical• Directed Pharmacology Dept = company’s preclinical biology research• Directed studies on mechanism of action of lead compounds• Implemented PKPD validation to determine minimal effective therapeutic exposure, in vivo tox & cognitive effects in animal models.Managerial• Up to 40 direct reports across 5 discipline-specific research groups.Clinical• Close interactions with Clinical Dept on analyses of phase III Alzhemed trials (psychometric measurement issues, neuroimaging and biomarkers)• Direct involvement with principal investigators, advisory boards, US Alzheimer’s Association and ADNI (Alzheimer Disease Neuroimaging Initiative)• Two invited external presentations on the phase III clinical program and its outcomesStrategic• Key involvement with Business Development on evaluation of in-licensing opportunities & due-diligence activities to support out-licensing efforts

Multiple project leaderships and initiatives. Most important:•Gamma-Secretase: Team leader for multi-disciplinary project comprised of up to 51 individuals from 8 departments Strategic• Global Alzheimer strategy coordinator• Alzheimer strategy leader, Neurology Disease Area Team• Designed, implemented, and secured corporate support for consortium between industry (AstraZeneca), government (Canadian Institutes of Health Research) and the voluntary sector (Alzheimer Society of Canada) to fund academic Alzheimer research in Canada. • Selected for international assignment in Sweden to contribute to development of the company’s Alzheimer strategy• Triage team with corporate Business Development Department in Neurology in Wilmington and Södertälje, with involvement ranging from identification and prioritization of novel opportunities, through due diligence investigations for corporate in-licensing.

Project Leadership• Amyloid A-lowering strategies, ultimately identifying inhibitors of beta- and gamma-secretases, with efforts ranging from cellular and cell-free assay development through lead identification and gamma-secretase enzyme isolation• Participated in development of novel transgenic mouse models• Responsible for managing interactions with corporate sponsor Schering-PloughManagerial• Direct reports included up to 9 individuals within the Biochemistry DepartmentStrategic• Participated in Business Development reviews of in-licensing opportunities• Represented research program in out-licensing discussions

Project Leadership• Established amyloid research program as part of corporate Alzheimer research effort.• Developed antibodies, recombinant proteins and several transgenic mouse models that were broadly shared to establish multiple key academic collaborations.• Seminal papers published on APP biology, Abeta characterization in Alzheimer brain, and APP-proteoglycan interactions which provided background to establishment of the Neurochem R&D program through collaboration with Neurochem’s founding scientists.Managerial• Direct reports included up to 7 individuals, including two students, two postdocs and two visiting scientists.Strategic• Leadership of “Alzheimer’s Task Force” focused an amyloid, kinase inhibition and growth factors.

Research• Cloned atrial natriuretic hormone that was later moved into clinical development.• One of the original cloners of the gene and cDNA for the human amyloid precursor protein (APP). Seminal publication on identification of one of the APP forms.• Wrote the research proposal that led to the establishment of the company’s neurobiology program.Managerial• Direct reports included up to five technicians and research assistants.• Developed and managed nucleotide synthesis capabilities as service for company’s cloning efforts.

Postdoctoral, Genetics, Molecular Genetics

Phd, Genetics, Molecular Biology

Ba, Ms, Biochemistry & Molecular Biology